France Has Not Invested Enough to Prepare for the Threat Posed by Alzheimer’s Disease

 The president of France Alzheimer, Joël Jaouen, and the director of the Global Coalition on Aging, Mike Hodin, warn in an op-ed for ‘Le Monde’ about the government’s disengagement in terms of financing disease prevention and access to care. This piece originally appeared in French.

 France, like almost every developed country in the world, is aging – a demographic fact that will lead to new public health challenges as significant as the COVID-19 pandemic. Today, more than 20% of the population is 65 years or older. By 2050, that number will rise to nearly 30%.

The aging of France all but guarantees a continuous rise in diseases that target the elderly. And perhaps the most devastating is Alzheimer’s – a disease that robs people of their memories, their independence, and their right to age with dignity. 

The big question is: Is France taking the actions needed to prepare for the looming Alzheimer’s pandemic? 

Unfortunately, the answer is a disappointing “no” – the current government is not investing adequately to prepare for the coming Alzheimer’s crisis. In fact, the country has taken several steps backward. And, in many ways, the crisis is already here. 

Today, more than 1.2 million people in France are living with Alzheimer’s and other dementias – a figure that will inevitably rise with the aging population. This devastating disease became the fourth leading cause of death in France in 2018, before the COVID-19 pandemic.

 To help stakeholders gauge France’s ability to meet this challenge, the Global Coalition on Aging and Alzheimer’s Disease International released the 2021 Alzheimer’s Innovation Readiness Index. The Index examines progress against several important measures of readiness, including a country’s policy and political commitment, early detection and diagnosis efforts, access to care and other factors. 

Overall, France currently ranks in the middle of the pack among European countries. Yet there are troubling signs that France risks falling behind. 

Most importantly, France’s political leaders have reneged on previous funding commitments to Alzheimer’s, signaling a lack of political will to address this slow-moving pandemic. 

Overall federal funding is down considerably compared to the €1.6 billion commitment of the Sarkozy years. In the Hollande administration, investment fell to €470 million and was spread over multiple diseases.

Restoring funding to previous levels is desperately needed to improve France’s diagnostic infrastructure, which is critical to ensuring early detection of the disease and putting people on the right care pathways before it’s too late. 

France also needs to make sizable investments to boost the country’s supply of trained caregivers. This is essential not simply to create enough supply to meet coming demand, but also to provide relief to family members and loved ones often shoulder this responsibility. As of 2015, these informal caregivers were already providing about €14 billion worth of care – a figure that is surely higher today and completely unsustainable.

According to the Index, France also ranks near the bottom in terms of access to care. This is also because prescriptions for Alzheimer’s therapies have plunged following the health ministry’s 2018 decision to cut all reimbursements.

Reimbursement strategies for Alzheimer’s drugs should also be revisited. This will produce better health outcomes for people who rely on current therapies and boost incentives for investments in new breakthroughs that can slow disease progression. 

President Macron’s new government — and the soon-to-be-elected French parliamentarians — have a unique opportunity to change course, by boosting funding in these key areas. In doing so, they can help France reassume the leadership position it held during the implementation of the 2008-2012 Alzheimer Plan and reduce the long-term economic and social burden of Alzheimer’s. At the same time, they can dramatically improve the lives of millions of its older citizens, their family members and loved ones who will be impacted by this devastating disease. 

Source: Le Monde

Latest Developments

We keep our members and partners in touch with the most recent updates and opinions in the worldwide dialogue on population longevity and related issues.

What Old Age Might Be Like for Today’s 30-Year-Olds

Get ready for a new old age. With the U.S. fertility rate in a decadelong slump and the life expectancy of 65-year-old Americans approaching roughly 85, our aging nation is likely to grow older by midcentury, as the ratio of young to old continues to decline. The trend is likely to upend how our society is organized, making life very different for today’s 30-year-olds when they reach their 60s compared with life for 60-year-olds now.

World Population Reaches 8bn As It Grows Older

The world’s population reached 8bn people on Tuesday and will hit 9bn in 15 years as it experiences an unprecedented surge in the number of older people, according to the latest UN data. The global fertility rate has more than halved since the 1950s to 2.3 births per woman. With mortality also falling, the number of people aged 65 and over is expected to rise from 783mn in 2022 to 1bn by 2030 and reach 1.4bn by 2043, the UN population data revealed.

Global Coalition on Aging (GCOA) Launches Cross-Sector Alliance Committed to Health Innovation at High-Level Forum on The Silver Economy

Today, the Global Coalition on Aging (GCOA), along with cross-sector stakeholders representing patient advocacy, policy, industry, and academic communities, announced the launch of the Alliance for Health Innovation at the High-Level Forum on the Silver Economy in New York. The Alliance is dedicated to establishing the importance of innovation in achieving healthy aging and health equity through investments, policy reforms, and strategic partnerships.

Japan Must Face Up to Growing Danger of Drug-resistant Germs

In the wake of more than 6.4 million COVID-19 deaths worldwide and unprecedented economic destruction, the global community has no excuse to be caught unprepared for the next pandemic. Yet right now, a devastating parallel plague is already underway and worsening. Some years, it is killing well over 1 million people, according to medical journal The Lancet.

A Bipartisan Bill Could Prevent The Next Pandemic

In Washington, Republicans and Democrats are typically at loggerheads when it comes to healthcare policy. Just consider the recent Inflation Reduction Act, which made extensive changes to Medicare and also extended Affordable Care Act subsidies. Every single congressional Democrat voted for the legislation, while every single member of the GOP voted against it. But occasionally, a bill is such an obviously good idea, and so desperately needed, that it commands significant bipartisan support. The PASTEUR Act, co-sponsored by 31 Democrats and 31 Republicans in the House and two members of each party in the Senate, is just such a bill.

Korea Must Act Now to Combat Growing AMR Threat

Public officials are overlooking one of the gravest long-term threats to the Korean people, the health system, and economy: antimicrobial resistance (AMR). Some pathogens ― bacteria, fungi, parasites, and viruses ― have evolved strains that resist the antimicrobial medications we currently have available to fight them. Health care professionals often must watch helplessly as patients succumb to infections that antibiotics could once have easily beaten. They know that new antimicrobials, including and especially antibiotics, could easily gain the victory ― but they have none at their disposal.

Policy Statement on the Impact of Price Negotiations on Innovation, Healthy Aging and Equity

As the CEO of the Global Coalition on Aging (GCOA) and a newly formed cross-sector Alliance for Health Innovation, we write to express our deep concern with the current legislation that allows for price “negotiations” in Medicare – a thinly veiled signal for America’s plunge into price controls that will have a devastating and adverse impact on biopharmaceutical innovation and our nations’ ability to support healthy aging.